Sera Prognostics Q3 revenue $29k, net loss $7.9M; PRIME study data locked

SERA PROGNOSTICS, INC.

2024-Q3 EPS reported -$0.74 revenue$53,000

Revenue fell to $29k from $42k YoY; net loss widened to $7.9M from $7.2M.
Operating expenses $8.9M, up 8% YoY; SG&A $5.4M due to growth investments.
PRIME study database locked in Sept; results planned for 2025 conferences and journal submission.
Direct-to-consumer PreTRM testing via website launched Oct 1; TV awareness campaign with Dennis Quaid and Meg Ryan.
Ambient whole blood collection lowers cost of goods and boosts lab capacity for scalability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.